Vericel (VCEL) Projected to Post Quarterly Earnings on Thursday

Vericel (NASDAQ:VCEL) will likely be announcing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of $0.0575 per share and revenue of $77.95 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:30 AM ET.

Vericel (NASDAQ:VCEL) last posted its quarterly earnings data on Thursday, July 30th. The biotechnology company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.07. Vericel had a return on equity of 6.91% and a net margin of 7.91%. The business had revenue of $77.46 million for the quarter, compared to analyst estimates of $72.70 million. During the same period in the previous year, the company posted ($0.01) earnings per share. The firm’s revenue for the quarter was up 22.5% on a year-over-year basis. On average, analysts expect Vericel to post $0.54 EPS for the current fiscal year and $0.84 EPS for the next fiscal year.

Vericel Stock Performance

NASDAQ VCEL opened at $41.09 on Thursday. Vericel has a twelve month low of $28.95 and a twelve month high of $49.32. The stock has a market capitalization of $2.10 billion, a PE ratio of 87.43 and a beta of 1.02. The stock has a 50-day simple moving average of $40.63 and a 200 day simple moving average of $38.62.

Analysts Set New Price Targets

A number of research firms have issued reports on VCEL. HC Wainwright reaffirmed a “buy” rating and issued a $70.00 target price on shares of Vericel in a report on Tuesday, July 28th. TD Cowen upped their price target on Vericel from $55.00 to $58.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Wall Street Zen raised Vericel from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Weiss Ratings raised Vericel from a “sell (d+)” rating to a “hold (c)” rating in a research report on Friday, July 31st. Finally, Truist Financial lowered their price objective on shares of Vericel from $58.00 to $52.00 and set a “buy” rating on the stock in a research note on Wednesday, October 14th. Four research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $57.20.

About Vericel

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient’s own cells or biologic materials to support tissue repair and healing.

Vericel’s primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults.